Repligen (NASDAQ:RGEN) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research note issued to investors on Sunday morning.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Wednesday, September 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. HSBC started coverage on shares of Repligen in a research report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price for the company. Wells Fargo & Company decreased their target price on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. Finally, Evercore ISI raised their target price on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $169.62.

Repligen Stock Down 1.3%

Shares of RGEN stock opened at $152.60 on Friday. The firm has a fifty day moving average of $128.81 and a 200-day moving average of $126.33. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a market capitalization of $8.59 billion, a price-to-earnings ratio of -610.38, a P/E/G ratio of 2.82 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the prior year, the company earned $0.40 EPS. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 1.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 80 shares during the last quarter. Alliance Wealth Advisors LLC UT lifted its stake in Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 89 shares in the last quarter. Drive Wealth Management LLC raised its position in Repligen by 2.5% in the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 93 shares in the last quarter. Hilltop National Bank raised its position in Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 95 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Repligen by 4.3% in the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.